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Abstract 
 
Objective(s) 
Opioid abuse is still remained a major mental health problem, a criminal legal issue and may cause ischemic 
brain changes including stroke and brain edema. In the present study, we investigated whether spontaneously 
withdrawal syndrome might affect stroke outcomes. 
Materials and Methods 
Addiction was induced by progressive incremental doses of morphine over 7 days. Behavioral signs of 
withdrawal were observed 24, 48 and 72 hr after morphine deprivation and total withdrawal score was 
determined. Cerebral ischemia was induced 18-22 hr after the last morphine injection by placing a natural 
clot into the middle cerebral artery (MCA). Neurological deficits were evaluated at 2, 24 and 48 hr after 
ischemia induction, and infarct size and brain edema were determined at 48 hr after stroke. 
Results 
Morphine withdrawal animals showed a significant increase in total withdrawal score and decrease of weight 
gain during the 72 hr after the last morphine injection. Compared to the addicted and control animals, infarct 
volume and brain edema were significantly increased in the morphine deprived animals (P< 0.05) at 48 hr 
after cerebral ischemia. Also, neurological deficits were higher in the morphine-withdrawn rats at 48 hr after 
stroke (P< 0.05).  
Conclusion 
Our data indicates that spontaneous withdrawal syndrome may worsen stroke outcomes. Further 
investigations are necessary to elucidate mechanisms of opiate withdrawal syndrome on stroke. 
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Introduction 
According to the report of world health 
organization, stroke is the second leading 
cause of death and the first cause of major 
adult disability in the world (1). Among the 
stroke patients, 85-90% of the cases are 
ischemic stroke with a predominant (75-80%) 
cause of cerebral arterial thrombosis and 
majorities of ischemic episodes occurring as a 
result of occlusion of the middle cerebral 
artery (MCA) or its branches (2, 3). Leading 
pathogenic mechanisms of cerebral ischemia 
include energy failure, elevation of 
intracellular Ca
2+ level, excitotoxicity, 
spreading depression, generation of free 
radicals, blood brain barrier disruption, 
inflammation and apoptosis (2).  
Recreational drug abuse is one of the most 
important risk factors for stroke in young adults 
(4). High rate of both ischemic and hemorrhagic 
stroke following opiate users have been 
described and there are several reports showing a 
broad range of neurologic complications in 
opiate users including embolic stroke and brain 
edema (5-7). Brain autopsy of patients that died 
from opiate heroin intoxication had presented 
cerebral edema (6).   
Opiates are used in medicine as analgesic 
drugs and abused for their recreational effects 
(8). There are numerous studies which 
controversially indicate neuroprotective and 
neurotoxic properties of opioids (9-11). Chronic 
exposure to these compounds leads to tolerance 
and physical dependence which are 
characteristics of opiate addiction. Following 
chronic administration of morphine, termination 
of the drug leads to withdrawal syndrome which 
is characterized by severe pathophysiological 
and behavioral manifestations (8, 12). It has 
been reported that opiate withdrawal syndrome 
causes neurodegenerative alterations including 
increased neuronal excitability and apoptosis, 
blood brain barrier (BBB) dysfunction and 
oxidative stress (2, 13-16). To the best of our 
knowledge, whether withdrawal from morphine 
in the addicted humans or animals can affect 
stroke outcomes has not yet been reported. 
Since opiate addiction is an illegal behavior 
in most countries, stroke addicted-patients or 
their relatives may prefer to keep it secret from 
health care providers or physicians and hence, 
they may go through opiate withdrawal 
syndrome during hospitalization. Therefore, 
studies in this area have clinical importance. In 
the present investigation we studied, for the 
first time, the effect of withdrawal from 
morphine on infarct size, brain edema and 
neurological deficits after stroke in rat.  
 
Materials and Methods 
Animals and treatments  
Animals  were  handled  in  accordance          
with  criteria  outlined  in  the  Guide  for               
Care  and  Use  of  Laboratory  Animals            
(NIH US publication 86-23 revised 1985; 
http://oacu.od.nih.gov/regs/guide/guidex.htm) 
and the experiments were approved by the 
University Research Council guidelines for 
conducting animal studies. Adequate measures 
were taken to minimize pain or discomfort of 
the animals. A total of 30 male Wistar rats 
weighting 250 to 300 g were maintained on a 
12 hr light-dark cycle, with food and water 
available ad libitum. Eight animals were non-
dependent and considered as control (vehicle) 
and 22 rats were subjected to morphine 
dependence. Dependence was induced by 
repeated subcutaneous injections of morphine 
sulfate (Darou-Pakhsh, Tehran, Iran) daily at 
13 PM as previously reported (8). In brief, 
morphine doses were dissolved in a volume of 
2 ml/kg saline and progressively increased for 
7 days initiating with 6, then 16, 26, 36, 46, 56 
and 66 mg/kg by a single dose. Control group 
was treated with saline following the same 
procedure. Both non-dependent (n= 8) and 
morphine dependent (n= 16) animals were 
gone under the surgery of embolic stroke at 
18-22 hr after the last injection of saline or 
morphine (day 8), respectively. Then the 
dependent rats were randomly divided into two 
groups of spontaneously morphine withdrawal 
or morphine dependent animals by terminating 
or continuing the last dose of morphine 
injection (66 mg/kg), respectively. The 
remaining 6 rats were equally divided into 3 
dependent and 3 withdrawal ones and used as 
sham-operated animals, accordingly. For 
sham-operated animals, the surgery was the  
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same except for injection of 5 µl saline into the 
MCA. 
   
Measurement of withdrawal syndromes 
Spontaneous withdrawal syndromes were 
induced by terminating morphine injection and 
observed for 30 min in circular Plexiglas 
boxes at 24 hr after the last morphine injection 
(day 8) and, 24 and 48 hr after stoke induction 
(days 9 and 10) as shown in Figure 1.   
Animals’ reactions were observed individually 
by an observer who was unaware of the 
treatments animals received. Total withdrawal 
score (TWS) was determined using the method 
described in detail before (8). Briefly, 20 
distinct withdrawal behaviors (16 scale): 
jumping, rearing, walk sniffing, sniffing, wet 
dog shakes, head shakes, body grooming, face 
wiping, penis licking, chewing, teeth 
chattering, swallowing, writhing, fore paw 
tremor, weight loss percentage and dysphoria 
time percentage; (2 ordinal): ptosis and 
diarrhea; and (2 checked) behaviors: 
irritability and eye twitch were scored. Body 
weight was measured daily during induction of 
morphine dependency and before each 
withdrawal observing periods.  
 
Induction of embolic stroke 
Rats were anesthetized with 1.5% halothane in 
a 21% O2 and 79% N2 mixture. Embolic stroke 
was induced by placing a preformed clot into 
the middle cerebral artery (MCA) as reported 
in detail before (17). Briefly, a longitudinal 
incision of 1.5 cm in length was made in the 
midline of the ventral cervical skin. The right 
common carotid artery, internal carotid artery, 
and external carotid artery were exposed. The 
distal portion of the external carotid artery was 
ligated and cut. A modified PE-50 tube with 
the 20 mm clot was connected to a 50-µl 
Hamilton  lock  syringe,  and  advanced           
17-19 mm in the internal carotid artery until its 
tip was inside of MCA. The clot was then 
injected and the catheter was removed. The 
wound was closed, and the animal was 
returned to its cage. Rectal temperature was 
maintained at   36.5±0.5 
oC with a heating pad 
throughout the surgical procedures. Blood gases 
and glucose and blood pressure were measured 5 
min before and after embolization. For sham-
operated animals, the surgery was the same 
except for injection of 5 µl saline into the MCA. 
The surgeon was blinded to the drug treatment 
regimen of animals he was working on.  
 
Measurement of infarct volumes and brain 
edema 
The quantification of infarct volume has been 
previously described in detail (17). Briefly, for 
these analyses rats were killed at 48 hr after 
MCA occlusion. The brains were removed from 
the skull, and using a brain matrix, the forebrain 
was sliced coronally at 2 mm intervals. A total of 
6 coronal sections were collected, and these were 
incubated with a 2% 2, 3, 5- triphenyltetrazolum 
chloride solution (TTC; Sigma, UK) at 37 ºC, 
and fixed by immersion in a 10% phosphate-
buffered formalin solution (Figure 3). The 
stained brain sections were scanned (Canon, 
CanoScan 9900f) and analyzed. The total 
volume of each hemisphere and infarction was 
determined by integration of the distance of the 6 
sections. Infarctions were adjusted to the size of 
contralateral hemisphere by applying the 
following formula: Infarct volume= (volume of 
left hemisphere-(volume of right hemisphere-
measured infarct volume))/ volume of left 
hemisphere. Brain edema was determined by 
using the following formula: Edema= (volume 
of right hemisphere-volume of left 
hemisphere)/volume of left hemisphere. The 
infarction volume and brain edema were 
expressed as percentages. For these analyses, the 
experimenter was blinded to the treatment 
assignations.  
 
Neurological deficits evaluation 
Neurological deficits were recorded at 2, 24 
and 48 hr after embolic stroke and determined 
with a modified 6-point scoring system (17) as 
follows: 0, no observable deficit; 1, forelimb 
flexion; 2, forelimb flexion plus decreased 
resistance to lateral push; 3, unidirectional 
circling; 4, unidirectional circling plus 
decreased level of consciousness; and 5, death. 
 
Statistical analysis  
Infarct volume and brain edema were 
presented as mean±SEM and were analyzed  
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with one-way ANOVA. Percentage of body 
weight changes (compared to the weight 
before the first injection) and total withdrawal 
score (TWS) were presented as mean±SEM 
and were analyzed by two-way repeated 
measure ANOVA or two-way ANOVA 
followed by Tukey’s test, respectively. 
Neurological deficits are reported as medians 
and interquartile ranges (25th and 75th 
percentiles), and were analyzed with Mann-
Whitney U test. A value of P< 0.05 was 
considered to be statistically significant. 
 
Results 
Weight changes 
The weight gain was monitored daily 
throughout morphine treatment and 
withdrawal, as shown in Figure 1. An increase 
of 4.5% and 3.5% in weight gain was observed 
in the control and morphine treated rats during 
the 8 days of experiment, respectively. This 
difference was not statistically significant. At 
24 hr (day 2 after the last morphine injection) 
after stroke induction, weight gain reduced in 
control, dependent  and morphine withdrawal 
animals by 5.8±1.14%, 3.9±.81 and 
11.04±1.15%, respectively, which was 
significantly  different  between  the  groups           
(P< 0.01). A maximum of significant 
difference in weight reduction was observed 
between morphine deprived animals and the 
other groups at 48 hr (day 3 after the last 
morphine  injection)  after  stroke  induction        
(P< 0.001). At this time point, weight 
reductions in the control, morphine dependent 
and morphine withdrawal animals were 
7.6±1.3%, 7.97±.66 and 18.25±1.73%, 
respectively (P< 0.001). 
 
Withdrawal syndrome 
Morphine-withdrawn animals showed 
behavioral signs of opiate withdrawal and the 
total withdrawal score (TWS) was considered 
as an index of abstinence throughout our 
experiments (Figure 2). While at the day 8             
(24 hr after the last morphine injection) there 
was no significant difference in TWS between 
control and morphine treated animals, 
withdrawal signs were significantly increased 
in morphine-deprived rats at 24 and 48 hr after 
stroke (days 2 and 3 after the last morphine 
injection; P< 0.001). Also, compared to 24 hr 
after stroke (day 2 after the last injection), 
TWS was increased in the morphine-deprived 
animals at 48 hr after cerebral ischemia onset 
(P< 0.05), as shown in Figure 2.  
 
 
 
 
Figure 1. Evaluation of weight change compared to the 
weight before the first injection. Body weight of each 
rat was measured before the injection in each day, 
before stroke induction (24 hr after the last morphine 
injection, day 8) or at 24 and 48 hr after stroke. Results 
are expressed as mean±SEM. **P< 0.01; ***P< 0.001 
compared to the control (saline) or morphine dependent 
group at the same time point. D= day. The lower and the 
upper arrows show the day of last morphine injection 
and stroke induction, respectively.    
 
 
 
 
Figure 2. Evaluation of total withdrawal scores (TWS) 
in non-dependent (control), morphine dependent or 
withdrawal rats before stroke induction (24 hr after the 
last morphine injection= day 8) or at 24 and 48 hr after 
stroke. Data are expressed as Mean±SEM. **P< 0.01; 
***P< 0.001 compared to the control or dependent 
animals at the same time. #P<0.05 compared to the 
same group at different time points.   
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Infarct volume and brain edema 
We did not observe any cerebral infarction or 
brain edema in the morphine withdrawal or 
dependent sham-operated animals. The mean 
infarct  volumes  in  control,  morphine              
and morphine-deprived animals were 
26.95±4.46%, 23.74±2.83 and 39.67±3.5%, 
respectively (Figure 3A). Compared to the 
control group, infarct volume in the morphine 
withdrawal  rats  was  increased  by  45%          
(P< 0.05). The mean brain edema in control, 
morphine-dependent and morphine withdrawal 
rats were 6.9±1.24, 5.45±1.3 and 10.44±1, 
respectively. Morphine-deprivation worsened 
brain edema compared to the control and 
morphine dependent groups when measured at 
48 hr after embolic stroke (P< 0.05; Figure 
3B). There were no significant differences in 
infarct volume or brain edema between control 
and morphine dependent animals. 
 
 
 
 
Figure 3. Morphine withdrawal worsens infarct volume 
(A) and brain edema (B) in the rats subjected to embolic 
cerebral ischemia. Infarct volume and brain edema were 
measured from TTC stained brain sections that were 
obtained 48 hr after embolic stroke (3 days after 
morphine deprivation). The data are presented as 
mean±SEM. *P< 0.05 compared to the control and 
morphine dependent rats.   
Table 1. Morphine withdrawal worsens neurological 
deficits in the rats subjected to embolic cerebral 
ischemia. 
Neurological deficits were measured by a five-score 
scale at 2, 24 and 48 hr after embolic cerebral ischemia 
onset. The data are presented as median, 25th and 75th 
percentiles (percentiles in the parentheses). Non 
parametric Mann-Whitney U test showed a significant 
difference between morphine withdrawal animals and 
the other two groups at 48 hr after stroke.
*P< 0.05 
compared to the control group at the same time. 
 
Neurological deficits evaluation 
Neurological deficits at 2, 24 and 48 hr after 
stroke were evaluated. The data are shown in 
Table 1. Compared to the control and 
morphine dependent groups, morphine-
deprived animals showed a higher score of 
neurological deficits at 48 hr after MCA 
embolization (P< 0.05). There were no 
significant difference between neurological 
scores of control, morphine dependent or 
withdrawal animals at 2 and 24 hr after stroke. 
No neurological deficit was observed in the 
sham operated rats. 
 
Discussion  
This is the first study to show that deprivation 
from morphine can deteriorate stroke 
outcomes in the addicted animals. To the best 
of our knowledge, there are no other 
publications discussing the effect of morphine 
withdrawal syndrome on cerebral ischemia 
outcomes. To mimic the human stroke and 
withdrawal syndrome, we chose the embolic 
model of stroke and spontaneously morphine 
withdrawal syndrome in our experiments. 
Brain injury after an ischemic attack is an 
evolving process that can continue for days 
after injury (18-20). During the delayed phase 
of cerebral ischemia, which may last for 
several days or even weeks, secondary 
phenomena such as inflammation, apoptotic 
cell death and vasogenic edema may 
contribute to further progression of brain 
injury (18). In the present study, we found that 
morphine withdrawal worsened infarct size, 
brain edema and neurological function in the 
    Groups    
Hours 
Control Morphine  Withdrawal 
2   4 (3-4.75)  3.5 (3-4.75)  4 (3-4.75) 
24  4 (2.25-4)  2.5 (2-5)  4.5 (2.25-5) 
48   3 (2.25-3.75)  2 (1-5)  5 (3.5-5)
*  
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dependent rats subjected to the embolic model 
of middle cerebral artery occlusion (MCAO). 
There was no significant difference in stroke 
outcome between addicted and non-addicted 
animals after focal embolic cerebral ischemia 
(P> 0.05).  
Most studies implemented to date have used 
opioid receptor antagonist-precipitated 
withdrawal syndrome. This experimental 
method however differs from the clinical 
setting where the opiate withdrawal syndrome 
occurs as a result of drug intake cessation. 
Spontaneously morphine withdrawal 
syndrome however induces milder behavioral 
modulation than the naloxone-precipitated one 
(21), although it has been suggested that 40 hr 
after the last morphine administration, 
spontaneous morphine withdrawal symptoms 
showed no difference with the naloxone-
precipitated one (22). Therefore, spontaneous 
withdrawal syndrome induced by cessation of 
morphine in the addicted animals more closely 
resembles the clinical conditions and may be 
better in future translation from bench to 
bedside. In the current study, we observed the 
classical signs in the spontaneous withdrawal 
model by depriving the dependent animals 
from morphine. Morphine-withdrawn animals 
showed behavioral signs of opiate withdrawal 
and the total withdrawal score was gradually 
increased as the interval of last morphine 
injection and testing time was increased. As 
expected, our data showed that weight loss of 
morphine withdrawal animals after stroke 
induction was significantly higher than the 
control  and  morphine  dependent  groups        
(P< 0.05). 
The possible neuropathology and 
neurodegeneration mechanisms of worsening 
stroke outcomes by morphine withdrawal 
syndrome are still not well known.  However, 
there are some similar mechanisms in the 
pathophysiology of stroke and opiate 
withdrawal syndrome which may have 
neurodegenerative or neurotoxic effects 
following stroke in the opiate withdrawal 
condition. First, excessive or prolonged 
stimulation of glutamate receptors, particularly 
N-methyl-D-aspartate (NMDA) receptors, 
which results in disruption of cellular ion 
homeostasis, oxidative stress, degeneration 
and death of neurons in a process called 
excitotoxicity, is one of the major 
pathophysiologies of stroke (2, 18). It has been 
reported that morphine withdrawal syndrome 
also augmented excitatory glutamate 
neurotransmitter release and subsequently 
increased neuronal excitability during 
morphine withdrawal (13, 22).  Accordingly, 
NMDA receptor antagonists could disrupt 
opiate withdrawal signs (14, 23). Hence, it can 
be speculated that morphine withdrawal 
syndrome may have augmented excitotoxicity 
of ischemic neurons and then raised neural 
death after stroke. Second, both cerebral 
ischemia (18, 24) and morphine withdrawal 
syndrome (15) induce apoptotic cell death in 
the brain. Third, blood brain barrier (BBB) 
disruption is one of the leading mechanisms of 
stroke pathology (2, 18) and spontaneous 
withdrawal of morphine also leads to BBB 
dysfunction and brain edema (16). Finally, 
oxidative stress may play a role in both 
morphine induced withdrawal neurotoxicity 
and stroke induced neurodegeneration (2, 16, 
18). Therefore, the above shared pathologic 
mechanisms in the cerebral ischemia and 
morphine withdrawal syndrome may have 
additive or even synergistic neurodegenerative 
deleterious effects on stroke outcome of 
morphine deprived animals.  
In the present study, we did not observe any 
significant difference in stroke outcome 
between morphine-dependent or independent 
rats. In agreement with our results, it has been 
reported that there was no difference in stroke 
outcome between drug-associated and non-
drug associated patients (4). Neuroprotective 
effects of δ and κ opioid receptor agonists (25) 
and also µ agonists (11) have been reported in 
animal models of cerebral ischemia. 
Paradoxically, neuroprotective effect of 
naloxone, a non-selective opioid receptor 
antagonist, in ischemic brain injury has been 
demonstrated (10). One reason that our 
findings are not parallel with the other 
investigators  (11,  25),  is  that  they                   
have described neuroprotection of opiate 
receptor agonists in normal but not   
morphine-addicted animals. Therefore, down- 
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regulation of endogenous opioid peptides or 
opiate receptors which happens during morphine 
addiction, may affect neuroprotective properties 
of these compounds.   
 
Conclusion 
The present study indicates for the first time, that 
spontaneous withdrawal syndrome may worsen 
infarct size, brain edema and neurological 
deficits after stroke. However, further 
investigations are necessary to elucidate the 
exact effects and pathophysiologic mechanisms 
of opiate withdrawal syndrome on stroke.  
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